Loxatias 10 Capsule contains Loxapine 10 mg, an antipsychotic agent belonging to the dibenzoxazepine class, primarily indicated for the treatment of schizophrenia and other psychotic disorders. Loxapine exerts its therapeutic effects by modulating neurotransmitter activity in the central nervous system, particularly through antagonism of dopamine D2 receptors and serotonin 5-HT2 receptors, thereby helping to restore the chemical balance in the brain. This action alleviates symptoms such as hallucinations, delusions, agitation, and disorganized thinking. Loxatias 10 Capsule is generally prescribed for patients exhibiting acute or chronic psychotic episodes and may be used as part of a comprehensive treatment plan including psychosocial interventions. The medication should be administered under strict medical supervision, with dosing individualized based on clinical response and tolerability. Common side effects may include sedation, dry mouth, dizziness, and extrapyramidal symptoms, necessitating careful monitoring. Caution is advised in patients with a history of cardiovascular disorders, seizures, or hepatic impairment. Loxatias 10 Capsule is contraindicated in individuals with known hypersensitivity to Loxapine or related compounds. Regular follow-up is essential to assess efficacy and detect potential adverse effects early, ensuring optimal therapeutic outcomes.